PharmaZell is a leading independent manufacturer of niche active pharmaceutical ingredients (API's) used to treat respiratory, inflammatory, bowel, liver and pulmonary diseases.
Headquartered in Raubling (near Munich), the company operates four state-of-the-art production and R&D sites in Germany, Italy and India collectively employing over 900 employees globally.
PharmaZell operates in a sector with attractive long-term market dynamics underpinned by an ageing population and increasing prevalence of chronic diseases. The global market for small molecule API's is estimated to be worth over $70 billion annually. Given its scale and market leadership the company is also well positioned to benefit from further consolidation in a fragmented market and the longstanding and ongoing trend towards outsourcing which benefits specialised manufacturers like PharmaZell.
In 2021, PharmaZell and France-based Novasep, a leading CDMO focused on complex small molecules and ADCs entered into exclusive negotiations to create a leading European platform in the attractive API manufacturing and CDMO space with a complementary set of differentiated technologies and highly diversified base of blue-chip pharma and biotech customers.
To learn more about the company, click here.